Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position
18 juil. 2022 07h05 HE
|
Entera Bio Ltd.
JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the...
Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company’s President of Research & Development to Pursue Outside Opportunities
17 juin 2022 17h00 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, June 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that Dr....
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
16 mai 2022 08h00 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of...
Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights
12 mai 2022 08h00 HE
|
Entera Bio Ltd.
Registrational study design for lead clinical asset, EB613, as the first oral PTH anabolic to treat post-menopausal women at high risk of osteoporosis, is underwayCompany reschedules conference call...
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
05 mai 2022 08h00 HE
|
Entera Bio Ltd.
— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include optimized oral delivery of specific molecules for various indications — BOSTON and JERUSALEM, May ...
Entera Bio to Report First Quarter 2022 Financial Results on May 12
28 avr. 2022 08h00 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, April 28, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
Entera Bio to Present at 2022 Maxim Virtual Growth Conference
22 mars 2022 08h00 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 22, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the Company...
Entera Bio Reports Financial Results for the Year Ended December 31, 2021
08 mars 2022 06h30 HE
|
Entera Bio Ltd.
— EB613 expected to commence pivotal Phase 3 Osteoporosis trial in 2022 —— New EB612 formulation for Hypoparathyroidism trial planned in 2022 —— Oral delivery technology platform advances with more...
Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022
03 mars 2022 09h50 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, March 03, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today it will report...
Entera Bio to Present at Aegis Virtual Conference on February 23rd
17 févr. 2022 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Israel, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced that the...